Considering HX103 is an EGFR-TKI-based probe and mirrors the binding of the drugs to the EGFR kinase domain, it was then asked whether HX103-based FACS would show predictive value for drug response in patients with EGFR-mutant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.